-
Under the increasing pressure of new drug research and development, pharmaceutical companies have begun to adjust the layout of innovation pipelines
Time of Update: 2023-02-01
In the future, as new drug research and development becomes more and more difficult and costly, the industry believes that more and more pharmaceutical companies will adjust their overall strategies based on the company's situation.
-
Domestic pharmaceutical companies compete for the blue ocean of the innovative drug market, and multiple tracks will become the focus of competition
Time of Update: 2023-02-01
In the future, under the continuous layout of enterprises, more new breakthroughs are expected in the field of innovative traditional Chinese medicine.
In the future, under the continuous layout of enterprises, more new breakthroughs are expected in the field of innovative traditional Chinese medicine.
-
The field of APIs has "turned over", and the performance of a large number of enterprises has increased significantly
Time of Update: 2023-02-01
【Pharmaceutical Network Market Analysis】 Recently, with the gradual liberalization of epidemic prevention and control, the pharmaceutical market has attracted much attention from the capital market, e
-
Ministry of Civil Affairs: Establish a direct hotline between urban and rural communities and the pharmacies of medical institutions
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];On January 11, the joint prevention and control mechanism of the State Council held a press conference to introduce the relevant situation of epidemic prevention and control in key institutions and key places.
-
The CRO sector has moved up, and there is a stock 20CM up limit!
Time of Update: 2023-02-01
【Pharmaceutical Network Pharmaceutical Stock Market】January 11 news, CRO sector changes to rise, individual stocks, Nuotai Biotech 20CM up limit, Sirnaomics rose more than 9%, in addition, Kailaiying, Kanglong Chemical, Medixi, Zhaoyan New Drug, etc.
-
When import substitution of pharmaceutical equipment is underway! The head enterprise may take the lead: Chutian Technology VS Dongfulong
Time of Update: 2023-02-01
Source: The company's annual report, pharmaceutical network collation and mapping Fourth, scientific research Chutian Technology has continued to increase its R&D investment in recent years and has maintained a high proportion of growth.
-
Montmorillonite related concept stocks exploded! Many stocks such as Kangzhi Pharmaceutical had a 20CM price limit
Time of Update: 2023-02-01
As of the close of trading on January 3, the montmorillonite scattered index rose by more than 10% on the day, of which 5 stocks were up and down, namely Kangzhi Pharmaceutical, Tongyuan Pharmaceutical, Yiming Pharmaceutical, Fangsheng Pharmaceutical, China Resources Shuanghe, and many head stocks even had a 20CM price limit.
-
The traditional Chinese medicine sector will continue to strengthen, and the long-term development in these areas is also promising
Time of Update: 2023-02-01
In recent years, while continuously encouraging the innovation of traditional Chinese medicines and accelerating the review and approval, domestic policies are also further focusing on the quality, cl
-
In 2023, the pharmaceutical industry will continue to set off a wave of cooperation!
Time of Update: 2023-02-01
It is understood that before that, Biocytogen provided Hansen Pharmaceutical with candidate fully human antibody molecules for its selected targets generated by the "Thousand Mouse AntibodiesTM" project, and Hansen Pharmaceutical exercised the right to choose after completing the evaluation of candidate antibody molecules to reach the license agreement.
-
WuXi Biologics rises more than 6%! For a license-out deal with GSK
Time of Update: 2023-02-01
In addition to WuXi Biologics, companies with self-developed bispecific antibody technology platforms such as Harbour Biologics have also received hundreds of millions of dollars in transactions through external licensing and cooperation.
-
Coenzyme Q10 was snapped up, and related concept stocks attracted attention!
Time of Update: 2023-02-01
In addition to King Dawei, it is reported that Lily shares said that orders for products including coenzyme Q10 have increased sharply recently, and the supply of products has exceeded demand, and the company has produced at full capacity by adjusting production lines.
-
The popular rhubarb, how much room for growth in the future?
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];As a commonly used variety of bulk Chinese medicinal materials, the market of rhubarb in recent years can be described as rising, attracting widespread attention in the industry.
-
Pharmaceutical companies pay close attention to the diabetes drug market, and the research and development of new drugs is accelerating
Time of Update: 2023-02-01
【Pharmaceutical Network Market Analysis】The field of diabetes treatment has always been one of the hot spots in the global pharmaceutical field, and with the acceleration of the global aging process a
-
The eighth batch of centralized procurement of large varieties game: Pfizer and others compete for the 60 billion market!
Time of Update: 2023-02-01
Among the multinational original research enterprises, Pfizer, Sanofi, Merck, Lundbeck, AstraZeneca, Eisai and other enterprises are listed, of which Pfizer has the largest number of products, and 3 varieties are to be included, with cefoperazone sulbactam injection and voriconazole injection having a high market share.
-
Medical beauty concept stocks collectively strengthened! Xingkerong Pharmaceutical soared 37%, and the blonde rabbi rose to the limit
Time of Update: 2023-02-01
【Pharmaceutical Network Pharmaceutical Stock Market】 On January 16, medical beauty concept stocks collectively strengthened, such as Xingkerong Pharmaceutical soared 37%, Jinfa Rabi rose to the limit, Aier Ophthalmology, Guangzheng Ophthalmology, Haohaisheng, Aimeike, Bloomage Biotechnology and a large number of other companies followed.
-
Zhejiang will temporarily include 15 kinds of drugs in the scope of medical insurance payment from the 6th
Time of Update: 2023-02-01
js?cdnversion='+~(-new Date()/36e5)];Medical security bureaus of cities and counties (cities and districts): In order to effectively respond to the new changes in the situation of the new coronavirus infection epidemic and the new challenges of prevention and control, meet the drug needs of patients and reduce the medical burden of patients, with the approval of the National Medical Security Administration, 15 drugs such as "compound aminophenolamine capsules" were temporarily included in the scope of medical insurance payment (see annex).
-
The State Food and Drug Administration released the 63rd batch of generic drug reference preparations
Time of Update: 2023-02-01
After the review and determination of the Expert Committee for the Consistency Evaluation of the Quality and Efficacy of Generic Drugs of the State Medical Products Administration, the list of refere
-
The traditional Chinese medicine sector has changed! Kangyuan Pharmaceutical rose more than 6%, and Dong Ejiao rose nearly 5%
Time of Update: 2023-02-01
News on January 12, the traditional Chinese medicine sector changed, in terms of individual stocks, Kangyuan Pharmaceutical rose by more than 6%, and Dong'a Jiao rose by nearly 5%, in addition, Jianmin Group, Pian Zixi, Zhongsheng Pharmaceutical, etc.
-
Disease control experts: At this stage, it is difficult for XBB strains to form a large-scale epidemic
Time of Update: 2023-02-01
XBB, an Omicron variant circulating in Europe and the United States with enhanced immune evasion ability, as it was detected in people quarantined in China, XBB quickly attracted attention, and in a series of branches of XBB, the most noteworthy is the "XBB.
-
The "take medicine" market has returned? More than 200 pharmaceutical-themed funds achieved positive returns
Time of Update: 2023-02-01
According to Databao's statistics, in the past five trading days (December 29 to January 5), about 139 listed companies in Shanghai and Shenzhen have been investigated by institutions.
